{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:44:30Z","timestamp":1761176670017,"version":"build-2065373602"},"reference-count":12,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2006,11,1]],"date-time":"2006-11-01T00:00:00Z","timestamp":1162339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Clinique et Biologique"],"published-print":{"date-parts":[[2006,11]]},"DOI":"10.1016\/j.tracli.2006.11.007","type":"journal-article","created":{"date-parts":[[2006,12,23]],"date-time":"2006-12-23T07:14:17Z","timestamp":1166858057000},"page":"307-311","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["vCJD and\u00a0blood transfusion: risk assessment in\u00a0the\u00a0United Kingdom"],"prefix":"10.1016","volume":"13","author":[{"given":"S.A.","family":"Dobra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.G.","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.tracli.2006.11.007_bib1","series-title":"Creutzfeldt\u2013Jacob disease: managing the risk of transmission by blood, plasma and tissues","article-title":"Risk assessments for variant Creutzfeldt\u2013Jacob disease and blood transfusion: a perspective from the UK","author":"Bennett","year":"2006"},{"key":"10.1016\/j.tracli.2006.11.007_bib2","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1057\/palgrave.jors.2601899","article-title":"Assessing the risk of vCJD transmission via surgery: models for uncertainty and complexity","volume":"56","author":"Bennett","year":"2005","journal-title":"J. Operational. Res. Soc."},{"key":"10.1016\/j.tracli.2006.11.007_bib3","unstructured":"Det Norske Veritas. Risk assessment of exposure to vCJD infectivity in blood and blood products. February 2003 for Dept of Health, London, available at www.dnv.com."},{"key":"10.1016\/j.tracli.2006.11.007_bib4","unstructured":"SEAC. Position statement on TSE infectivity in blood, July 2006, available at www.seac.gov.uk."},{"key":"10.1016\/j.tracli.2006.11.007_bib5","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1128\/JVI.76.9.4649-4650.2002","article-title":"Scrapie infectivity in hamster blood is not associated with platelets","volume":"76","author":"Holada","year":"2002","journal-title":"J. Virol."},{"key":"10.1016\/j.tracli.2006.11.007_bib6","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1002\/path.1580","article-title":"Prevalence of lymphoreticular prion protein accumulation in UK tissue samples","volume":"203","author":"Hilton","year":"2004","journal-title":"J. Pathol."},{"key":"10.1016\/j.tracli.2006.11.007_bib7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S0140-6736(04)15486-X","article-title":"Possible transmission of variant CJD by blood transfusion","volume":"363","author":"Llewelyn","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2006.11.007_bib8","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1136\/bmj.38804.511644.55","article-title":"Variant Creutzfeldt\u2013Jacob disease: prion protein genotype analysis of positive appendix samples from a retrospective prevalence study","volume":"332","author":"Ironside","year":"2006","journal-title":"BMJ"},{"key":"10.1016\/j.tracli.2006.11.007_bib9","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0140-6736(04)16811-6","article-title":"Preclinical vCJD after blood transfusion in a PRNP Codon 129 heterozygous patient","volume":"363","author":"Peden","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.tracli.2006.11.007_bib10","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1474-4422(06)70413-6","article-title":"Predicting susceptibility and incubation time of human-to-human transmission of vCJD","volume":"5","author":"Bishop","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.tracli.2006.11.007_bib11","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(04)16812-8","article-title":"Effectiveness of leucodepletion for removal of infectivity of TSEs from blood","volume":"364","author":"Gregori","year":"2004","journal-title":"Lancet"},{"year":"2001","series-title":"Management of possible exposure to CJD through medical procedures: a consultation paper","key":"10.1016\/j.tracli.2006.11.007_bib12"}],"container-title":["Transfusion Clinique et Biologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782006001492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1246782006001492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:27:58Z","timestamp":1761128878000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1246782006001492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,11]]},"references-count":12,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,11]]}},"alternative-id":["S1246782006001492"],"URL":"https:\/\/doi.org\/10.1016\/j.tracli.2006.11.007","relation":{},"ISSN":["1246-7820"],"issn-type":[{"type":"print","value":"1246-7820"}],"subject":[],"published":{"date-parts":[[2006,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"vCJD and\u00a0blood transfusion: risk assessment in\u00a0the\u00a0United Kingdom","name":"articletitle","label":"Article Title"},{"value":"Transfusion Clinique et Biologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tracli.2006.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2007 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}